Advertisement

Index by author

October 01, 2017; Volume 363,Issue 1

  1. Wixted, William E.

    1. Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress
      John G. Yonchuk, Joseph P. Foley, Brian J. Bolognese, Gregory Logan, William E. Wixted, Jen-Pyng Kou, Diana G. Chalupowicz, Heidi G. Feldser, Yolanda Sanchez, Hong Nie, James F. Callahan, Jeffrey K. Kerns and Patricia L. Podolin
      Journal of Pharmacology and Experimental Therapeutics October 2017, 363 (1) 114-125; DOI: https://doi.org/10.1124/jpet.117.241794

  2. Wolf, C. Roland

    1. Open Access
      Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites
      De Lin, Rumen Kostov, Jeffrey T.-J. Huang, Colin J. Henderson and C. Roland Wolf
      Journal of Pharmacology and Experimental Therapeutics October 2017, 363 (1) 12-19; DOI: https://doi.org/10.1124/jpet.117.243246

  3. Yonchuk, John G.

    1. Characterization of the Potent, Selective Nrf2 Activator, 3-(Pyridin-3-Ylsulfonyl)-5-(Trifluoromethyl)-2H-Chromen-2-One, in Cellular and In Vivo Models of Pulmonary Oxidative Stress
      John G. Yonchuk, Joseph P. Foley, Brian J. Bolognese, Gregory Logan, William E. Wixted, Jen-Pyng Kou, Diana G. Chalupowicz, Heidi G. Feldser, Yolanda Sanchez, Hong Nie, James F. Callahan, Jeffrey K. Kerns and Patricia L. Podolin
      Journal of Pharmacology and Experimental Therapeutics October 2017, 363 (1) 114-125; DOI: https://doi.org/10.1124/jpet.117.241794

  4. Zalevsky, Jonathan

    1. NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential
      Takahiro Miyazaki, Irene Y. Choi, Werner Rubas, Neel K. Anand, Cherie Ali, Juli Evans, Hema Gursahani, Marlene Hennessy, Grace Kim, Daniel McWeeney, Juergen Pfeiffer, Phi Quach, David Gauvin, Timothy A. Riley, Jennifer A. Riggs, Kathleen Gogas, Jonathan Zalevsky and Stephen K. Doberstein
      Journal of Pharmacology and Experimental Therapeutics October 2017, 363 (1) 104-113; DOI: https://doi.org/10.1124/jpet.117.243030

  5. Zhou, Haihong

    1. Enhancing Studies of Pharmacodynamic Mechanisms via Measurements of Metabolic Flux: Fundamental Concepts and Guiding Principles for Using Stable Isotope Tracers
      Natalie A. Daurio, Sheng-Ping Wang, Ying Chen, Haihong Zhou, David G. McLaren, Thomas P. Roddy, Douglas G. Johns, Denise Milot, Takhar Kasumov, Mark D. Erion, David E. Kelley and Stephen F. Previs
      Journal of Pharmacology and Experimental Therapeutics October 2017, 363 (1) 80-91; DOI: https://doi.org/10.1124/jpet.117.241091

  6. Zielinska, Marta

    1. New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration
      Maciej Salaga, Anna Mokrowiecka, Marta Zielinska, Ewa Malecka-Panas, Radzislaw Kordek, Elzbieta Kamysz and Jakub Fichna
      Journal of Pharmacology and Experimental Therapeutics October 2017, 363 (1) 92-103; DOI: https://doi.org/10.1124/jpet.117.242586
« Previous (Pages : 5 6 7 8 9 ... 9)next »
Back to top

In this issue

Advertisement